Amphastar Pharmaceuticals 향후 성장

Future 기준 점검 2/6

Amphastar Pharmaceuticals (는) 각각 연간 5.4% 및 4.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 31.6% 로 예상됩니다.

핵심 정보

5.4%

이익 성장률

5.02%

EPS 성장률

Pharmaceuticals 이익 성장	14.6%
매출 성장률	4.2%
향후 자기자본이익률	31.64%
애널리스트 커버리지	Good
마지막 업데이트	15 Dec 2025

최근 향후 성장 업데이트

Recent updates

After Protracted Sell-Off, Amphastar Looks Like A Value Pick

Sep 23

Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price

Jul 01

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt

Apr 04

Amphastar Pharmaceuticals: A Gradual Strategy

Feb 19

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well

Jan 03

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares

Dec 16

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 28

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Oct 25

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Sep 15

Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines

Sep 12

Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance

Sep 10 Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.

Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Aug 27

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 05

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Jul 01

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11

이익 및 매출 성장 예측

NasdaqGS:AMPH - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	792	173	182	220	5
12/31/2026	764	158	169	211	6
12/31/2025	727	157	119	211	6
9/30/2025	723	112	111	152	N/A
6/30/2025	723	135	110	160	N/A
3/31/2025	731	142	150	193	N/A
12/31/2024	732	160	172	213	N/A
9/30/2024	724	158	170	208	N/A
6/30/2024	713	167	178	213	N/A
3/31/2024	676	155	161	198	N/A
12/31/2023	644	138	145	184	N/A
9/30/2023	601	135	140	175	N/A
6/30/2023	541	102	100	131	N/A
3/31/2023	519	93	51	79	N/A
12/31/2022	499	91	65	89	N/A
9/30/2022	485	77	90	114	N/A
6/30/2022	477	91	70	97	N/A
3/31/2022	455	81	100	126	N/A
12/31/2021	438	62	71	98	N/A
9/30/2021	413	36	45	74	N/A
6/30/2021	384	10	52	81	N/A
3/31/2021	368	2	45	79	N/A
12/31/2020	350	1	23	57	N/A
9/30/2020	337	7	13	46	N/A
6/30/2020	334	4	-11	25	N/A
3/31/2020	327	52	12	47	N/A
12/31/2019	322	49	0	42	N/A
9/30/2019	329	52	3	46	N/A
6/30/2019	324	53	N/A	73	N/A
3/31/2019	316	2	N/A	26	N/A
12/31/2018	295	-6	N/A	38	N/A
9/30/2018	265	-7	N/A	38	N/A
6/30/2018	248	-9	N/A	25	N/A
3/31/2018	242	-4	N/A	25	N/A
12/31/2017	240	4	N/A	39	N/A
9/30/2017	243	0	N/A	43	N/A
6/30/2017	250	4	N/A	42	N/A
3/31/2017	252	9	N/A	47	N/A
12/31/2016	255	10	N/A	39	N/A
9/30/2016	269	21	N/A	28	N/A
6/30/2016	268	14	N/A	30	N/A
3/31/2016	254	0	N/A	23	N/A
12/31/2015	252	-3	N/A	11	N/A
9/30/2015	230	-13	N/A	20	N/A
6/30/2015	226	-15	N/A	30	N/A
3/31/2015	221	-10	N/A	28	N/A
12/31/2014	210	-11	N/A	21	N/A

애널리스트 향후 성장 전망

수입 대 저축률: AMPH 의 연간 예상 수익 증가율(5.4%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: AMPH 의 연간 수익(5.4%)이 US 시장(16.2%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: AMPH 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: AMPH 의 수익(연간 4.2%)이 US 시장(연간 10.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: AMPH 의 수익(연간 4.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: AMPH의 자본 수익률은 3년 후 31.6%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/24 02:37
종가	2025/12/24 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Amphastar Pharmaceuticals, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Glen Santangelo	Barclays
Gary Nachman	BMO Capital Markets Equity Research
Jason Matthew Gerberry	BofA Global Research

Amphastar Pharmaceuticals 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates increase by 10%

Consensus EPS estimates increase by 24%

Price target decreased by 15% to US$32.40

Price target decreased by 16% to US$39.80

Price target decreased by 11% to US$50.00

Consensus EPS estimates fall by 14%

Recent updates

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 10%

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Amphastar Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Consensus EPS estimates increase by 24%

After Protracted Sell-Off, Amphastar Looks Like A Value Pick

Insufficient new directors

Investor sentiment improves as stock rises 41%

Second quarter 2025 earnings: EPS exceeds analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Amphastar Pharmaceuticals, Inc. Appoints David Gaugh to Serve as A Class I Director

Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index

Co-founder exercised options to buy US$5.1m worth of stock.

Price target decreased by 15% to US$32.40

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025

Investor sentiment deteriorates as stock falls 16%

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt

Co-founder exercised options and sold US$3.0m worth of stock

Price target decreased by 16% to US$39.80

Full year 2024 earnings: EPS misses analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Amphastar Pharmaceuticals: A Gradual Strategy

Price target decreased by 11% to US$50.00

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares

Lead Independent Director notifies of intention to sell stock

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Consensus EPS estimates fall by 14%

CFO, Executive VP of Finance notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Co-founder exercised options to buy US$5.0m worth of stock.

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines

Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance

New minor risk - Insider selling

Insider notifies of intention to sell stock

Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Lead Independent Director notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Executive VP of Finance notifies of intention to sell stock

Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Co-founder exercised options to buy US$4.1m worth of stock.

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

Reassessing Amphastar Pharmaceuticals

First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Price target decreased by 7.3% to US$62.60

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Co-founder exercised options and sold US$13m worth of stock

CFO, Executive VP of Finance notifies of intention to sell stock

Insider recently sold US$590k worth of stock

Investor sentiment deteriorates as stock falls 15%

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Full year 2023 earnings: EPS misses analyst expectations

Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023

Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chairman of the Board notifies of intention to sell stock

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today